Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy

Noriaki Sunaga, David S. Shames, Luc Girard, Michael Peyton, Jill E. Larsen, Hisao Imai, Junichi Sou, Mitsuo Sato, Noriko Yanagitani, Kyoichi Kaira, Yang Xie, Adi F. Gazdar, Masatomo Mori, John D. Minna

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic subtype of non - small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdown of oncogenic KRAS led to inhibition of in vitro and in vivo tumor growth in the KRAS-mutant NSCLC cells, but not in NSCLC cells that have wild-type KRAS (but mutant NRAS). Surprisingly, we did not see large-scale induction of cell death and the growth inhibitory effect was not complete. To further understand the ability of NSCLCs to grow despite selective removal of mutant KRAS expression, we conducted microarray expression profiling of NSCLC cell lines with or without mutant KRAS knockdown and isogenic human bronchial epithelial cell lines with and without oncogenic KRAS. We found that although the mitogen-activated protein kinase pathway is significantly downregulated after mutant KRAS knockdown, these NSCLCs showed increased levels of phospho-STAT3 and phospho - epidermal growth factor receptor, and variable changes in phospho-Akt. In addition, mutant KRAS knockdown sensitized the NSCLCs to p38 and EGFR inhibitors. Our findings suggest that targeting oncogenic KRAS by itself will not be sufficient treatment, but may offer possibilities of combining anti-KRAS strategies with other targeted drugs.

Original languageEnglish
Pages (from-to)336-346
Number of pages11
JournalMolecular Cancer Therapeutics
Volume10
Issue number2
DOIs
Publication statusPublished - Feb 2011
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Growth
Neoplasms
Therapeutics
Cell Line
Mitogen-Activated Protein Kinases
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Cell Death
Down-Regulation
Epithelial Cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. / Sunaga, Noriaki; Shames, David S.; Girard, Luc; Peyton, Michael; Larsen, Jill E.; Imai, Hisao; Sou, Junichi; Sato, Mitsuo; Yanagitani, Noriko; Kaira, Kyoichi; Xie, Yang; Gazdar, Adi F.; Mori, Masatomo; Minna, John D.

In: Molecular Cancer Therapeutics, Vol. 10, No. 2, 02.2011, p. 336-346.

Research output: Contribution to journalArticle

Sunaga, N, Shames, DS, Girard, L, Peyton, M, Larsen, JE, Imai, H, Sou, J, Sato, M, Yanagitani, N, Kaira, K, Xie, Y, Gazdar, AF, Mori, M & Minna, JD 2011, 'Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy', Molecular Cancer Therapeutics, vol. 10, no. 2, pp. 336-346. https://doi.org/10.1158/1535-7163.MCT-10-0750
Sunaga, Noriaki ; Shames, David S. ; Girard, Luc ; Peyton, Michael ; Larsen, Jill E. ; Imai, Hisao ; Sou, Junichi ; Sato, Mitsuo ; Yanagitani, Noriko ; Kaira, Kyoichi ; Xie, Yang ; Gazdar, Adi F. ; Mori, Masatomo ; Minna, John D. / Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. In: Molecular Cancer Therapeutics. 2011 ; Vol. 10, No. 2. pp. 336-346.
@article{ba13e2deba9a4c39b1d9bc5b989f4987,
title = "Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy",
abstract = "Oncogenic KRAS is found in more than 25{\%} of lung adenocarcinomas, the major histologic subtype of non - small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdown of oncogenic KRAS led to inhibition of in vitro and in vivo tumor growth in the KRAS-mutant NSCLC cells, but not in NSCLC cells that have wild-type KRAS (but mutant NRAS). Surprisingly, we did not see large-scale induction of cell death and the growth inhibitory effect was not complete. To further understand the ability of NSCLCs to grow despite selective removal of mutant KRAS expression, we conducted microarray expression profiling of NSCLC cell lines with or without mutant KRAS knockdown and isogenic human bronchial epithelial cell lines with and without oncogenic KRAS. We found that although the mitogen-activated protein kinase pathway is significantly downregulated after mutant KRAS knockdown, these NSCLCs showed increased levels of phospho-STAT3 and phospho - epidermal growth factor receptor, and variable changes in phospho-Akt. In addition, mutant KRAS knockdown sensitized the NSCLCs to p38 and EGFR inhibitors. Our findings suggest that targeting oncogenic KRAS by itself will not be sufficient treatment, but may offer possibilities of combining anti-KRAS strategies with other targeted drugs.",
author = "Noriaki Sunaga and Shames, {David S.} and Luc Girard and Michael Peyton and Larsen, {Jill E.} and Hisao Imai and Junichi Sou and Mitsuo Sato and Noriko Yanagitani and Kyoichi Kaira and Yang Xie and Gazdar, {Adi F.} and Masatomo Mori and Minna, {John D.}",
year = "2011",
month = "2",
doi = "10.1158/1535-7163.MCT-10-0750",
language = "English",
volume = "10",
pages = "336--346",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy

AU - Sunaga, Noriaki

AU - Shames, David S.

AU - Girard, Luc

AU - Peyton, Michael

AU - Larsen, Jill E.

AU - Imai, Hisao

AU - Sou, Junichi

AU - Sato, Mitsuo

AU - Yanagitani, Noriko

AU - Kaira, Kyoichi

AU - Xie, Yang

AU - Gazdar, Adi F.

AU - Mori, Masatomo

AU - Minna, John D.

PY - 2011/2

Y1 - 2011/2

N2 - Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic subtype of non - small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdown of oncogenic KRAS led to inhibition of in vitro and in vivo tumor growth in the KRAS-mutant NSCLC cells, but not in NSCLC cells that have wild-type KRAS (but mutant NRAS). Surprisingly, we did not see large-scale induction of cell death and the growth inhibitory effect was not complete. To further understand the ability of NSCLCs to grow despite selective removal of mutant KRAS expression, we conducted microarray expression profiling of NSCLC cell lines with or without mutant KRAS knockdown and isogenic human bronchial epithelial cell lines with and without oncogenic KRAS. We found that although the mitogen-activated protein kinase pathway is significantly downregulated after mutant KRAS knockdown, these NSCLCs showed increased levels of phospho-STAT3 and phospho - epidermal growth factor receptor, and variable changes in phospho-Akt. In addition, mutant KRAS knockdown sensitized the NSCLCs to p38 and EGFR inhibitors. Our findings suggest that targeting oncogenic KRAS by itself will not be sufficient treatment, but may offer possibilities of combining anti-KRAS strategies with other targeted drugs.

AB - Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic subtype of non - small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdown of oncogenic KRAS led to inhibition of in vitro and in vivo tumor growth in the KRAS-mutant NSCLC cells, but not in NSCLC cells that have wild-type KRAS (but mutant NRAS). Surprisingly, we did not see large-scale induction of cell death and the growth inhibitory effect was not complete. To further understand the ability of NSCLCs to grow despite selective removal of mutant KRAS expression, we conducted microarray expression profiling of NSCLC cell lines with or without mutant KRAS knockdown and isogenic human bronchial epithelial cell lines with and without oncogenic KRAS. We found that although the mitogen-activated protein kinase pathway is significantly downregulated after mutant KRAS knockdown, these NSCLCs showed increased levels of phospho-STAT3 and phospho - epidermal growth factor receptor, and variable changes in phospho-Akt. In addition, mutant KRAS knockdown sensitized the NSCLCs to p38 and EGFR inhibitors. Our findings suggest that targeting oncogenic KRAS by itself will not be sufficient treatment, but may offer possibilities of combining anti-KRAS strategies with other targeted drugs.

UR - http://www.scopus.com/inward/record.url?scp=79951823579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951823579&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0750

DO - 10.1158/1535-7163.MCT-10-0750

M3 - Article

C2 - 21306997

AN - SCOPUS:79951823579

VL - 10

SP - 336

EP - 346

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -